ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc.ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪2.73 M‬USD
−73.92USD
‪−98.30 M‬USD
0.00USD
‪1.07 M‬
Beta (1Y)
1.51
Employees (FY)
7
Change (1Y)
−7 −50.00%
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−14.04 M‬USD

About ZyVersa Therapeutics, Inc.


CEO
Stephen C. Glover
Headquarters
Weston
Founded
2014
FIGI
BBG01137LPK6
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ZVSA is 1.54 USD — it has decreased by −34.25% in the past 24 hours. Watch ZyVersa Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ZyVersa Therapeutics, Inc. stocks are traded under the ticker ZVSA.
ZVSA stock has fallen by −18.14% compared to the previous week, the month change is a −25.45% fall, over the last year ZyVersa Therapeutics, Inc. has showed a −94.82% decrease.
ZVSA reached its all-time high on Dec 12, 2022 with the price of 8,741.25 USD, and its all-time low was 1.88 USD and was reached on Nov 1, 2024. View more price dynamics on ZVSA chart.
See other stocks reaching their highest and lowest prices.
ZVSA stock is 89.55% volatile and has beta coefficient of 1.51. Track ZyVersa Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is ZyVersa Therapeutics, Inc. there?
Today ZyVersa Therapeutics, Inc. has the market capitalization of ‪2.73 M‬, it has decreased by −4.29% over the last week.
Yes, you can track ZyVersa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ZyVersa Therapeutics, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
ZVSA earnings for the last quarter are −3.31 USD per share, whereas the estimation was −2.20 USD resulting in a −50.45% surprise. The estimated earnings for the next quarter are −1.60 USD per share. See more details about ZyVersa Therapeutics, Inc. earnings.
ZVSA net income for the last quarter is ‪−2.76 M‬ USD, while the quarter before that showed ‪−2.83 M‬ USD of net income which accounts for 2.23% change. Track more ZyVersa Therapeutics, Inc. financial stats to get the full picture.
No, ZVSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 7, 2024, the company has 7.00 employees. See our rating of the largest employees — is ZyVersa Therapeutics, Inc. on this list?
Like other stocks, ZVSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ZyVersa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ZyVersa Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ZyVersa Therapeutics, Inc. stock shows the sell signal. See more of ZyVersa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.